Syndrome X: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
No edit summary
Line 1: Line 1:
{{Chronic stable angina]]
{{Chronic stable angina}}


{{CMG}}
{{CMG}}


''The terms '''Syndrome X''' or '''Metabolic syndrome X''' may also be referring to [[metabolic syndrome]].''
''The terms '''Syndrome X''' or '''Metabolic syndrome X''' may also be referring to [[metabolic syndrome]].''

Revision as of 00:56, 24 July 2011

Chronic stable angina Microchapters

Acute Coronary Syndrome Main Page

Home

Patient Information

Overview

Historical Perspective

Classification

Classic
Chronic Stable Angina
Atypical
Walk through Angina
Mixed Angina
Nocturnal Angina
Postprandial Angina
Cardiac Syndrome X
Vasospastic Angina

Differentiating Chronic Stable Angina from Acute Coronary Syndromes

Pathophysiology

Epidemiology and Demographics

Risk Stratification

Pretest Probability of CAD in a Patient with Angina

Prognosis

Diagnosis

History and Symptoms

Physical Examination

Test Selection Guideline for the Individual Basis

Laboratory Findings

Electrocardiogram

Exercise ECG

Chest X Ray

Myocardial Perfusion Scintigraphy with Pharmacologic Stress

Myocardial Perfusion Scintigraphy with Thallium

Echocardiography

Exercise Echocardiography

Computed coronary tomography angiography(CCTA)

Positron Emission Tomography

Ambulatory ST Segment Monitoring

Electron Beam Tomography

Cardiac Magnetic Resonance Imaging

Coronary Angiography

Treatment

Medical Therapy

Revascularization

PCI
CABG
Hybrid Coronary Revascularization

Alternative Therapies for Refractory Angina

Transmyocardial Revascularization (TMR)
Spinal Cord Stimulation (SCS)
Enhanced External Counter Pulsation (EECP)
ACC/AHA Guidelines for Alternative Therapies in patients with Refractory Angina

Discharge Care

Patient Follow-Up
Rehabilitation

Secondary Prevention

Guidelines for Asymptomatic Patients

Noninvasive Testing in Asymptomatic Patients
Risk Stratification by Coronary Angiography
Pharmacotherapy to Prevent MI and Death in Asymptomatic Patients

Landmark Trials

Case Studies

Case #1

Syndrome X On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Syndrome X

CDC onSyndrome X

Syndrome X in the news

Blogs on Syndrome X

to Hospitals Treating Syndrome X

Risk calculators and risk factors for Syndrome X

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

The terms Syndrome X or Metabolic syndrome X may also be referring to metabolic syndrome.

Synonyms and key words: Microvascular angina

Overview

(Cardiac) syndrome X is angina (chest pain) associated with objective evidence of myocardial ischemia in the setting of normal epicardial coronary arteries. It is thought to involve the coronary microvasculature rather than the large epicardial arteries.

Pathophysiology

In a large percentage of patients, there is a finding of systemic microvascular abnormalities, causing reduced blood flow in the microvasculature of the cardiac muscles. While numerous physiological mechanisms have been proposed, none have been proven.

Epidemiology and Demographics

Syndrome X occurs more often in young women. Some studies have found increased risk of other vasospastic disorders in syndrome X patients, such as migraine and Raynaud's phenomenon.

Natural history, complications, and prognosis

Syndrome X does not appear to be associated with an excess of major coronary events.

Risk Factors

Female gender and hypertrophy of the myocardium are associated with an excess risk of Syndrome X.

Other Conditions to Distinguish Syndrome X From

Syndrome X is a distinct diagnosis from Prinzmetal's angina which involves spasm of the main epicardial coronary arteries. Syndrome X involves spasm of the downstream microvasculature. Syndrome X must also be distinguished from esophageal spasm.

Diagnosis

Syndrome X is a diagnosis of exclusion. Typically this will necessitate both a clinical diagnosis, appropriate stress testing, and a coronary angiogram that meet the criteria below:

  • Some of these patients have documented reductions in coronary vasodilator reserve presumably due to abnormalities in the coronary microcirculation and can be shown to have true ischemia because their myocardium produces lactate rather than removing it during stress. While there is no formal definition for Syndrome X, the general consensus is that it entails all of the following:

Treatment

The mainstay of treatment in patients with Syndrome X are calcium channel blockers, such as nifedipine and diltiazem. Other therapies include:

ESC Guidelines for investigation in patients with Syndrome X (DO NOT EDIT)[1]

Class I

1. Resting echocardiogram in patients with angina and normal or non-obstructed coronary arteries to assess for presence of ventricular hypertrophy and/or diastolic dysfunction. (Level of Evidence: C)

Class IIb

1. Intracoronary acetylcholine during coronary arteriography, if the arteriogram is visually normal, to assess endothelium-dependent coronary flow reserve, and exclude vasospasm. (Level of Evidence: C)

2. Intracoronary ultrasound, coronary flow reserve, or FFR measurement to exclude missed obstructive lesions, if angiographic appearances are suggestive of a nonobstructive lesion rather than completely normal, and stress imaging techniques identify an extensive area of ischaemia. (Level of Evidence: C)

ESC Guidelines for pharmacological therapy to improve symptoms in patients with Syndrome X (DO NOT EDIT)[1]

Class I

1. Therapy with nitrates, beta blockers, and calcium channel blockers alone or in combination. (Level of Evidence: B)

2. Statin therapy in patients with hyperlipidaemia. (Level of Evidence: B)

3. ACE inhibitors in patients with hypertension. (Level of Evidence: C)

Class IIa

1. Trial of therapy with other anti-anginals including nicorandil and metabolic agents. (Level of Evidence: C)

Class IIb

1. Aminophylline for continued pain, despite Class I measures. (Level of Evidence: C)

2. Imipramine for continued pain, despite Class I measures. (Level of Evidence: C)

References

  1. 1.0 1.1 Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F; et al. (2006). "Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology". Eur Heart J. 27 (11): 1341–81. doi:10.1093/eurheartj/ehl001. PMID 16735367.


Review Articles

Template:SIB


Template:WikiDoc Sources